Bristol-Myers Squibb

Clinical Development Lead, Rheumatology (Senior Director)

Princeton, New Jersey, United States

Not SpecifiedCompensation
Senior (5 to 8 years), Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical Development, Medical AffairsIndustries

Requirements

Candidates should possess a Bachelor’s degree in a relevant scientific discipline, such as Biology, Pharmacology, or a related field, and hold a minimum of 8 years of experience in clinical development, with at least 5 years specifically focused on Rheumatology. Strong leadership skills and experience managing clinical trial teams are essential, along with a thorough understanding of global clinical development processes and regulatory requirements.

Responsibilities

The Clinical Development Lead will serve as the clinical point of accountability for the Development Team, responsible for the overall clinical development plan for assigned assets and indications, ensuring studies align with target label indications and meet regulatory, quality, medical, and access goals. They will manage clinical trial physicians, provide clinical content for regulatory submissions, and champion a quality-focused mindset within the team, representing Clinical Development in internal and external forums.

Skills

Clinical Development
Rheumatology
Clinical Trial Management
Regulatory Requirements
Global Clinical Development
Clinical Trial Physicians
Medical Writing

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI